Moderna vs Pfizer: Study suggests one is better against COVID-19

A new study suggests the Moderna vaccine may generate twice as many antibodies against COVID-19 as the Pfizer shot. Moderna announced last week that it has completed the application process to the U.S. Food and Drug Administration for full approval of its COVID-19 vaccine.

According to a press release from the company, the process has been ongoing for months, as Moderna has been submitting data for what's called a Biologics License Application (BLA) on a rolling basis since June of this year. This specific license would be for people ages 18 and older.

Moderna Chief Executive Officer Stéphane Bancel called the completion of the process, "an important milestone in our battle against COVID-19."

The latest submission to the FDA includes data from Moderna's phase 3 efficacy study, which showed a 93% efficacy rate through six months after the second dose.

It's not immediately clear how long the FDA will take to go over the data and issue a decision. Earlier this week, the administration approved the Pfizer-BioNTech COVID vaccine for people 16 and older. That application began in May 2021, so should the FDA take a similar amount of time to rule on Moderna's application, a decision might be expected by November 2021. Pfizer is currently the only COVID-19 vaccine with the FDA's full approval. #COVID19 #WakeUpCLT #Vaccine

[SubFlow]

Study suggests natural immunity is even better.